Successful production start for HyNap-Dasa in Xspray's unique full-scale production line
STOCKHOLM – June 27, 2019. Xspray Pharma (Nasdaq First North: XSPRAY) today announced that the first of two full-scale production lines, producing the company's amorphous formulation on a commercial scale, is now installed and tested in Milan, Italy. This means that the development of the company's first product candidate HyNap-Dasa, an amorphous version of Sprycel® (dasatinib), is proceeding according to plan.Xspray Pharma's production process at NerPharma in Milan, Italy, is developed for commercial production of drugs formulated with the company’s HyNap technology. The production